1. Home
  2. ACR vs CGEN Comparison

ACR vs CGEN Comparison

Compare ACR & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ACR
  • CGEN
  • Stock Information
  • Founded
  • ACR 2005
  • CGEN 1993
  • Country
  • ACR United States
  • CGEN Israel
  • Employees
  • ACR N/A
  • CGEN N/A
  • Industry
  • ACR Real Estate Investment Trusts
  • CGEN Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ACR Real Estate
  • CGEN Health Care
  • Exchange
  • ACR Nasdaq
  • CGEN Nasdaq
  • Market Cap
  • ACR 139.0M
  • CGEN 125.3M
  • IPO Year
  • ACR N/A
  • CGEN 2000
  • Fundamental
  • Price
  • ACR $20.80
  • CGEN $1.38
  • Analyst Decision
  • ACR Buy
  • CGEN
  • Analyst Count
  • ACR 3
  • CGEN 0
  • Target Price
  • ACR $20.50
  • CGEN N/A
  • AVG Volume (30 Days)
  • ACR 17.5K
  • CGEN 243.8K
  • Earning Date
  • ACR 10-29-2025
  • CGEN 11-11-2025
  • Dividend Yield
  • ACR N/A
  • CGEN N/A
  • EPS Growth
  • ACR N/A
  • CGEN N/A
  • EPS
  • ACR 0.04
  • CGEN N/A
  • Revenue
  • ACR $86,599,000.00
  • CGEN $22,144,000.00
  • Revenue This Year
  • ACR $10.76
  • CGEN N/A
  • Revenue Next Year
  • ACR N/A
  • CGEN $159.40
  • P/E Ratio
  • ACR $505.80
  • CGEN N/A
  • Revenue Growth
  • ACR 12.74
  • CGEN N/A
  • 52 Week Low
  • ACR $14.87
  • CGEN $1.13
  • 52 Week High
  • ACR $23.81
  • CGEN $2.66
  • Technical
  • Relative Strength Index (RSI)
  • ACR 56.88
  • CGEN 41.92
  • Support Level
  • ACR $20.75
  • CGEN $1.39
  • Resistance Level
  • ACR $21.21
  • CGEN $1.47
  • Average True Range (ATR)
  • ACR 0.34
  • CGEN 0.06
  • MACD
  • ACR -0.10
  • CGEN -0.00
  • Stochastic Oscillator
  • ACR 34.74
  • CGEN 33.33

About ACR ACRES Commercial Realty Corp.

ACRES Commercial Realty Corp is a commercial real estate investment trust that focuses on originating, holding and managing commercial real estate (CRE) mortgage loans and equity investments in commercial real estate properties through direct ownership and joint ventures. The company invests in commercial real-estate-related assets, including whole loans, A notes, B notes, mezzanine loans, and mortgage-related securities, as well as commercial finance assets, which include other asset-backed securities, senior secured corporate loans, equipment leases and notes, trust preferred securities, debt tranches of collateralize debt obligations, and private equity investments mainly issued by financial institutions.

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

Share on Social Networks: